Can less be more? new trial aims to cut harsh side effects in HPV throat cancer treatment
NCT ID NCT06702033
First seen Jun 26, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This study is for people with HPV-related throat cancer. After surgery, patients receive lower-than-standard doses of radiation and sometimes chemotherapy, based on their risk level. The goal is to keep cancer from coming back while reducing side effects like weight loss. About 142 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cisplatin (chemotherapy) and radiation therapy (IMRT or IMPT)
- What this could lead to
- If successful, this could lead to a new standard of care that reduces harsh side effects from radiation and chemotherapy after surgery for HPV-related throat cancer.
- What could go wrong
- This is a Phase 2 trial with only 142 participants, so results are not definitive. Lowering treatment intensity might increase the risk of cancer recurrence.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV-RELATED OROPHARYNX SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sanford Cancer Center
RECRUITINGSioux Falls, South Dakota, 57104, United States
-
Sanford Roger Maris Cancer Center
RECRUITINGFargo, North Dakota, 58102, United States
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States